Argenx Se (ARGX) Prepaid Assets (2015 - 2026)
Argenx Se's (ARGX) quarterly Prepaid Assets came in at $572.0 million in Q2 2026, down 99.84% on a YoY basis from $362.7 billion in Q2 2025, and up 74.39% quarter-over-quarter from $328.0 million in Q4 2025.
Analysis
Argenx Se (ARGX) Prepaid Assets (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Prepaid Assets for 12 consecutive years, with $572.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets fell 99.84% year-over-year to $572.0 million; the trailing twelve-month figure through Jun 2026 stood at $572.0 million (down 99.84% YoY), and the FY2025 full-year result was $328.0 million, up 74.52% from the prior year.
- Prepaid Assets climbed to $572.0 million in Q2 2026 per ARGX's latest filing, from $328.0 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $362.7 billion in Q2 2025 and bottomed at $76.0 million in Q4 2022.
- Historically, Prepaid Assets has averaged $40.5 billion across 5 years, with a median of $179.4 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Prepaid Assets tumbled 99.87% in 2022, then jumped 202059.74% in 2025.
- Over 5 years, Prepaid Assets stood at $76.0 million in 2022, then soared by 76.36% to $134.1 million in 2023, then soared by 40.18% to $187.9 million in 2024, then soared by 74.52% to $328.0 million in 2025, then surged by 74.39% to $572.0 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $572.0 million, $328.0 million, and $362.7 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 572.00 Mn |
| Dec 31, 2025 | 328.00 Mn |
| Jun 30, 2025 | 362.72 Bn |
| Dec 31, 2024 | 187.95 Mn |
| Jun 30, 2024 | 179.42 Mn |
| Dec 31, 2023 | 134.07 Mn |
| Jun 30, 2023 | 138.83 Mn |
| Dec 31, 2022 | 76.02 Mn |
| Jun 30, 2022 | 82.31 Mn |
| Dec 31, 2021 | 58.95 Bn |
| Jun 30, 2021 | 62.40 Mn |
| Dec 31, 2020 | 27.12 Bn |
| Jun 30, 2020 | 11.97 Mn |
| Dec 31, 2019 | 9.99 Mn |
| Jun 30, 2019 | 9.36 Mn |
| Dec 31, 2018 | 3.42 Mn |
| Jun 30, 2018 | 5.63 Mn |
| Dec 31, 2017 | 2.75 Mn |
| Jun 30, 2017 | 2.59 Mn |
| Dec 31, 2016 | 2.32 Mn |